May 22 (Reuters) - The U.S. Food and Drug Administration on Monday approved Opiant Pharmaceuticals Inc's nalmefene-based nasal spray as a treatment for reversing opioid-related overdoses, the agency said.
British drugmaker Indivior Plc's recently acquired the drug through its buyout of Opiant Pharmaceuticals Inc in a deal worth $145 million.
(Reporting by Bhanvi Satija, Vaibhav Sadhamta and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments